Anita Chakraverty, Author at Labiotech.eu

About

Anita Chakraverty is a freelance medical journalist and science communicator. Outside work, she enjoys a good movie, long walks in the local woods, and trying to get into pretzel-like yoga poses.

Articles by Anita Chakraverty

News and Trends 17 May 2022

US Giant Apollo Bags Billion-Euro Partnership with Sofinnova

As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing…

May 17, 2022 - 3 minutesmins - By Anita Chakraverty

News and Trends 6 May 2022

Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast

Tapping into the increasingly sophisticated market for meat alternatives, the Swedish synthetic biology startup Melt&Marble has raised €5M in seed financing to fund the development of a fermented fat ingredient…

May 6, 2022 - 4 minutesmins - By Anita Chakraverty

world health organization genomics pathogen pandemic

News and Trends 5 Apr 2022

WHO Beefs up Worldwide Genomic Surveillance to Prevent Pandemics

The World Health Organization has released a 10-year plan to monitor the genetic make-up of pathogens across the globe. The strategy highlights how far genomics has come during the Covid-19…

April 5, 2022 - 4 minutesmins - By Anita Chakraverty

News and Trends 31 Mar 2022

Precision Medicine Startups Increase Focus on Data Access and Privacy

Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and ownership remains a key issue for many individuals. Sano Genetics is one of many firms…

March 31, 2022 - 4 minutesmins - By Anita Chakraverty

News and Trends 22 Mar 2022

Biotechs Carve out Niches in Cystic Fibrosis Treatment Space

Cystic fibrosis has proved resistant to treatments that provide long-lasting respite from the sticky mucus that affects the lungs and other organs. Emerging biotechs such as Kither Biotech as well…

March 22, 2022 - 5 minutesmins - By Anita Chakraverty

argenx efgartigimod treatment autoimmune disease myasthenia gravis

News and Trends 21 Dec 2021

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be…

December 21, 2021 - 4 minutesmins - By Anita Chakraverty

London UK venture capital adendra therapeutics apple tree partners

News and Trends 14 Dec 2021

ATP Blazes US Venture Capital Trail into European Biotech Startups

The US venture capital firm Apple Tree Partners (ATP) is making its first transatlantic foray by launching the UK immuno-oncology company Adrendra Therapeutics. This happens as US investors increasingly search…

December 14, 2021 - 4 minutesmins - By Anita Chakraverty

Medical anca associated vasculitis avacopan

News and Trends 1 Dec 2021

Targeted Drugs for Rare Autoimmune Disease Hit Regulatory Milestones

New, more targeted treatments are on the horizon for the rare autoimmune disease ANCA-associated vasculitis, with a nod towards European approval for a first-in-class drug and positive phase II results…

December 1, 2021 - 4 minutesmins - By Anita Chakraverty

Industrial biotech sustainability environment

News and Trends 18 Nov 2021

Sustainability in Focus as Two VCs Build Industrial Biotech Funds

As this month’s COP26 United Nations climate summit highlighted the climate change emergency, venture capital fundraises from Sofinnova and the European Circular Bioeconomy Fund have led the push for industrial…

November 18, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 12 Nov 2021

Big Pharma Strikes Megadeals In Targeted Protein Degradation

With many targeted protein degraders hitting the clinic, lucrative collaborations and acquisitions are being signed between biotech startups and big pharma in this upcoming area. Novartis, Pfizer, and Bayer have…

November 12, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 4 Nov 2021

Skilled Labor Shortages Impact Cell And Gene Therapy Manufacturing

Despite vast amounts of funding entering the cell and gene therapy field, the manufacture of these therapies is held back by skill shortages. Increasing training programs and automation could form…

November 4, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 22 Oct 2021

Gene-Edited T Cell Therapy Players Battle Safety Doubts

Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial.…

October 22, 2021 - 5 minutesmins - By Anita Chakraverty

Beyond Biotech - the podcast from Labiotech

View More

Newsletter Signup - Sidebar

"*" indicates required fields

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering